New study to reveal how standard brain tumor treatments impact immune response
NCT ID NCT07568782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the immune system changes in people with glioblastoma, an aggressive brain cancer, after they have surgery and chemotherapy. Researchers will take blood samples over six months to measure immune cells and signals. The goal is to understand the body's immune response to standard treatments, which may help improve future therapies. About 17 adults with suspected glioblastoma will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 17 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with newly diagnosed resectable glioblastoma undergoing fluorescence-guided resection and chemoradiotherapy according to the STUPP protocol. The study includes a prospective control cohort treated with fluorescence-guided resection and chemoradiotherapy only (i.e., without photodynamic therapy (PDT)) and a historical prospective cohort previously treated with intraoperative PDT (INDYGO and DOSINDYGO trials) combined with fluorescence-guided resection and chemoradiotherapy. All patients receive standard post-operative Stupp protocol. Peripheral blood samples are analyzed for systemic immune profiling.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient male or female ≥18 years * General status (WHO) of Performance status 0, 1 or 2 * Probable glioblastoma according to clinical and radiological criteria, * whose surgical indication was given in Multidisciplinary consultation meeting (RCP) of neurooncology, * Decision to treat the patient as part of the Clinical trial also taken in neuro-oncology RCP ("Multidisciplinary consultation meeting") * Patient operable on the basis of absence of cardiopulmonary disease history; a complete medical check-up sufficient to insure a post-operative state with normal daily life * Clinical neuro-oncological monitoring and long-term MRI scheduled at the hospital CHRU of Lille, center of reference of the region * Patient able to understand and sign voluntarily Informed consent * Patient able to adhere to the visit's calendar of the study and other imperatives of the protocol * Women of child-bearing potential should benefit of an effective contraception * For patients receiving hepatotoxic therapy in the long term, this treatment must be suspended during the 24h after taking 5-ALA * Patient assigned to an health insurance Exclusion Criteria: * Contraindications to 5-ALA (Gliolan®) * Porphyria * Taking photosensitizer treatment * Severe renal or hepatic impairment * Bilirubin\> 1.5 x maximum level, Alkaline Phosphatases and transaminases (ASAT)\> 2.5 x Maximum rates * Creatinine clearance \<30 mL / min; * Non-compliance with the rules of prevention of the transient risk of cutaneous photosensitization * Contraindications to surgery * Contraindications to magnetic resonance imaging (MRI) * Treatment with an experimental drug within 30 Days prior to the start of the study * Clinical follow-up impossible to perform for psychological, familial, social or geographical reasons, * Legal incapacity (persons deprived of their liberty or Guardianship or guardianship), * Pregnant or nursing women * Refusal to participate or sign the consent of the study * Soy allergy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glioblastoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Lille
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a trio of repurposed drugs shrink recurrent brain tumors?
- Can an existing drug boost bevacizumab against recurrent brain cancer?
- One extra radiation dose after standard brain cancer therapy: can it boost the immune system?
- Radioactive tracer lights up Oxygen-Starved brain tumors
- Can a common virus vaccine help fight brain cancer?
- Radioactive tiles target brain tumors in frail patients